Showing results (21-30 of 370) with videos related to
Sort By:
Pageof 37
Cancers|February 11, 2023
Preclinical Models of Low-Grade GliomasPushan Dasgupta, Veerakumar Balasubramanyian, John F de Groot, et al.Cancer Cell|March 12, 2015
Seek and destroy: relating cancer drivers to therapiesEmmanuel Martinez-Ledesma, John F de Groot, Roel G W VerhaakCNS Oncology|December 17, 2015
ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastomaNa Tosha N Gatson, Shiao-Pei S Weathers, John F de GrootAdvances in Experimental Medicine and Biology|January 1, 2022
Neurologic Toxicities of ImmunotherapyRebecca A Harrison, Nazanin K Majd, Sudhakar Tummala, et al.Oncotarget|September 13, 2015
Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagyJi Liang, Yuji Piao, Verlene Henry, et al.Cancer Research|March 9, 2005
The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivoJohn F de Groot, Ta Jen Liu, Gregory Fuller, et al.Journal of the American Statistical Association|March 9, 2026
Bayesian Nonparametric Common Atoms Regression for Generating Synthetic Controls in Clinical TrialsNoirrit Kiran Chandra, Abhra Sarkar, John F de Groot, et al.Current Neurology and Neuroscience Reports|April 26, 2006
Neurologic toxicities of cancer therapiesRobert Cavaliere, David SchiffCurrent Neurology and Neuroscience Reports|April 29, 2010
Management of low-grade gliomaNader Pouratian, David SchiffNeurology. Clinical Practice|November 7, 2013
Neuro-oncology: Five new thingsDavid Schiff, Benjamin PurowPageof 37